Predictable in IV sedation.

DUMEX

Diazemuls®

10mg diazepam in 2ml emulsion

The cream of IV sedation

PRESCRIBING INFORMATION

PRESENTATION Ampoules of a white opaque emulsion containing diazepam BP 10mg in 2ml.

Indications:

1. Sedation prior to procedures such as endoscopy, dentistry, cardiac catheterisation and cardioversion.
2. Premedication prior to general anaesthesia.
3. Control of acute muscle spasm due to tetanus or poisoning.
4. Control of convulsions; status epilepticus.
5. Management of severe acute anxiety or agitation including delirium tremens.

DOSAGE AND ADMINISTRATION

Diazemuls may be administered by slow intravenous injection (1ml per min), or by continuous infusion. Diazemuls should be drawn up into the syringe immediately prior to administration.

1. **Sedation:** 0.1 – 0.2 mg diazepam/kg body weight by iv injection.
2. **Premedication:** 0.1 – 0.2 mg diazepam/kg body weight by iv injection.
3. **Tetanus:** 0.1 – 0.3 mg diazepam/kg body weight by iv injection repeated every 1 – 4 hours as required. Alternativeiy, continuous infusion of 3 – 10 mg/kg body weight every 24 hours may be used.
4. **Status epilepticus:** An initial dose of 0.15 – 0.25 mg/kg body weight by iv injection repeated in 30 to 60 minutes if required, and followed if necessary by infusion of up to 3 mg/kg body weight over 24 hr.
5. **Anxiety and tension, acute muscle spasm, acute states of excitation, delirium tremens:** The usual dose is 10 mg repeated at intervals of 4 hours, or as required.

Elderly or debilitated patients: Elderly and debilitated patients are particularly sensitive to benzodiazepines. Dosage should initially be reduced to one half of the normal recommendations.

CONTRA-INDICATIONS, WARNINGS, ETC:

As with other benzodiazepine preparations: should not be used in phobic or obsessional states nor in the treatment of chronic psychosis. Treatment with diazepam may cause drowsiness and increase the patient's reaction time. Use with caution in patients with impairment of renal or hepatic function and in patients with pulmonary insufficiency or myasthenia gravis. Should not be used alone to treat depression or anxiety associated with depression. Amnesia may occur. In cases of loss or bereavement psychological adjustment may be inhibited by benzodiazepines. Disinhibiting effects may be manifested in various ways. Suicide may be precipitated in patients who are depressed and aggressive behaviour toward self and others may be precipitated. Extreme caution should therefore be used in prescribing benzodiazepines in patients with personality disorders. Physiological and psychological symptoms of withdrawal including depression may be associated with discontinuation of benzodiazepines even after normal therapeutic doses for short periods of time.

Pregnancy and Lactation: Diazepam crosses the placenta and should not be used during pregnancy unless considered essential. Large maternal doses administered during delivery may produce clinical effects in the newborn. Diazepam can be transmitted in breast milk and clinical effects may occur in the breast-fed infant.

Side Effects: May rarely cause local pain or thrombophlebitis. Rare instances of a local painless erythematous rash around the site of injection. Urticaria and, rarely, anaphylaxis have been reported.

Overdosage: CNS depression and coma. Treatment symptomatic.

PHARMACEUTICAL PRECAUTIONS: See Data Sheet

Pack Size & Cost: 10 × 2ml ampoules: NHS Price £6.29

Product Licence No: 10183/0001

Date of preparation: April 1989

(Diazemuls is a registered trademark)

Product Licence Holder: Dumex Ltd.,
Riverside Way,
UXBRIDGE,
Middx. UB8 2YF
Tel: Uxbridge (0895) 51144

Distributed in the UK by KabiVitrum Ltd

KV881/5/89

FAST W

ORKER

'Pepcid' PM,

working fast to relieve

the pain of ulcers,[1] quickly

restoring the well-being

of many patients.

This rapid relief, together

with fast, effective healing,[2]

is achieved in many patients

with a simple dosage of

just one small 40 mg

tablet at night.

PEPCID®PM 40

(famotidine) *mg*

ONE AT NIGHT CAN MAKE THEIR DAY

SPECIFICALLY DEVELOPED
FOR THE SUPPRESSION OF
NOCTURNAL ACID

PRECAUTIONS Exclude any likelihood of gastric carcinoma before using 'Pepcid' PM. Consider reducing the daily dose if creatinine clearance falls to or below 30 ml/min. 'Pepcid' PM is not recommended in pregnancy, nursing mothers or children.
SIDE EFFECTS Rarely, headache, dizziness, constipation, diarrhoea. Less frequently, dry mouth, nausea, vomiting, rash, abdominal discomfort, anorexia, fatigue.
BASIC NHS COST 20 mg tablets, £14.00 for 28-day calendar pack and £25.00 for bottles of 50. 40 mg tablets, £26.60 for 28-day calendar pack and £47.50 for bottles of 50.
Product Licence Numbers: 20 mg tablets, 0025/0215; 40 mg tablets 0025/0216. Issued March 1989.

▼Special reporting to the CSM required.
®denotes registered trademark of Merck & Co., Inc., Rahway, NJ, USA.

References

1. Rohner, H-G., and Gugler, R., *Amer. J. Med.*, 1986, *81* (Suppl. 4B) 13. 2. Dobrilla, G., *et al.*, *Scand. J. Gastroenterol.*, 1987, *22* (Suppl. 34), 21.

03-90 PCD.89.GB.4086.J.

Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.

colofac®

mebeverine

loosens the grip of IBS

Prescribing Information
Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml: Basic NHS price £3.50. **Indications:** 1. Irritable bowel syndrome. 2. Gastrointestinal spasm secondary to organic diseases. **Dosage and Administration:** Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** *Tablets:* 0512/0044: *Suspension:* 0512/0061. Further information is available on request to the Company.

duphar Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

C/Hosp Ad/1/88